Management of refractory bleeding post-cardiopulmonary bypass in an acute heparin-induced thrombocytopenia type II renal failure patient who underwent urgent cardiac surgery with bivalirudin (Angiox ® ) anticoagulation

Abstract

Acute heparin-induced thrombocytopenia (HIT) patients present a myriad of anticoagulation management challenges, in clinical settings where unfractionated heparin (UFH) is the traditional drug of choice. UFH use in cardiac surgery is a known entity that has been subject to rigorous research. Research has, thus, led to its unparalleled use and the development of well-established protocols for cardiac surgery. In comparison to UFH, bivalirudin use for acute HIT patients requiring urgent cardiac surgery with cardiopulmonary bypass (CPB) is still in its infancy. We describe the tailored post-CPB management of refractory bleeding in a 65-year-old infective endocarditis, acute HIT patient with renal failure who underwent urgent aortic valve replacement and mitral valve repair with bivalirudin anticoagulation. A management approach that entailed a combination of continuous venovenous haemofiltration (CVVH), 4-Factor prothrombin complex concentrate (PCC) (Beriplex), recombinant factor VIIa (rFactor VIIa) and desmopressin (DDAVP) were consecutively used post-operatively in theatre. Based on this case study experience, two modifications to institutional protocols are recommended. The first is the use of CVVH in theatre to eliminate bivalirudin in renal failure patients or in patients where bivalirudin elimination is prolonged. Secondly, a ‘rescue therapy/intervention’ algorithm for the swift identification of refractory bleeding post-CPB is also recommended. Rescue therapy agents, such as a 4-Factor PCCs and rFactor VIIa, should be incorporated into the protocol after a robust evidence-based search and agreement with the haematologist. The aim of these recommendations is to reduce the risk of bleeding associated with bivalirudin use for inexperienced institutions and experienced institutions alike, until larger randomized, controlled studies provide more in-depth knowledge to expand our clinical practice.

Keywords

cardiopulmonary bypass cardiac surgery heparin-induced thrombocytopenia bivalirudin direct thrombin inhibitors refractory bleeding HIT renal failure HIT positive acute heparin-induced thrombocytopenia

Get full access to this article

View all access options for this article.

References

Ahmed

Majeed

Powell

Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J 2007; 83: 575–582.

Rehfeldt

Barbara

DW.

Cardiopulmonary bypass without heparin. Semin Cardiothorac Vasc Anesth 2016; 20: 40–51.

Linkins

Dans

Moores

et al . Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e495S–530S.

Watson

Davidson

Keeling

Guidelines on the diagnosis and management of heparin-induced thrombocytopenia. Br J Haematol 2012; 159: 528–540.

Dyke

Smedira

Koster

et al . A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131: 533–539.

Koster

Dyke

Aldea

et al . Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007: 83: 572–577.

Warkentin

Greinacher

Koster

. Bivalirudin. Thromb Haemost 2008; 99: 830–839.

Besser

MacDonald

SG.

Acquired hypofibrinogenemia: current perspectives. J Blood Med 2016; 7: 217.

Greilich

Edson

Rutland

et al . Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot. J Cardiothorac Vasc Anesth 2015; 29: 303–310.

10.

Jooste

Machovec

Einhorn

et al . 3-Factor prothrombin complex concentrates in infants with refractory bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2016; 30: 1627–1631.